Providing the best Talent and Services for your team globally within the Life Science / Biotech sector
🚨 Sanofi Sues Sarepta Therapeutics Over US Patents for Gene Therapy Treatments 🚨 Sanofi's biotech arm, Genzyme Genetics, has filed a lawsuit against Sarepta Therapeutics in Delaware federal court, alleging patent infringement related to Sarepta's Duchenne muscular dystrophy (DMD) treatment, Elevidys. Genzyme claims that Sarepta's technology mimics their proprietary process for gene therapy delivery. 🧬 Key Points: -Patent Infringement: Genzyme accuses Sarepta of using their patented technology for modifying viruses in gene therapy treatments. -DMD Focus: DMD is a severe degenerative genetic disorder affecting primarily boys. Elevidys, approved by the FDA, is the first gene therapy for DMD. -Legal Action: Genzyme is seeking damages for the alleged infringement. This follows Sarepta’s recent legal victory against Regenxbio over the same drug. This legal battle highlights the intense competition and high stakes in the biopharma industry, especially in the rapidly advancing field of gene therapy. #GeneTherapy #Biopharma #PatentInfringement #Sanofi #Sarepta #DMD #Innovation #LegalNews #Healthcare
Providing the best Talent and Services for your team globally within the Life Science / Biotech sector
4mosource: https://www.reuters.com/legal/litigation/sanofi-sues-sarepta-over-us-patents-gene-therapy-treatments-2024-07-29/